media – Page 579 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Med-tech startup Metavention raises $65M, names new CEO

Metavention Inc., a startup developing a medical device to treat Type 2 diabetes, has closed on $65 million in venture capital and named former Torax Medical Inc. CEO Todd Berg its top executive
- Source: Business Journal
- 643
- January 10, 2018
Company Insight diabetes medical device
Latest Chinese Medical Device Regulatory Changes Affect Clinical Trials, Testing, Telehealth

The China Food and Drug Administration (CFDA) has announced new and updated regulations for medical device registration, testing and clinical trial requirements in the early days of 2018.
- Source: Emergo
- 805
- January 10, 2018
CFDA Clinical Trials medical device polices
Pfizer lines up an $830M alliance with Arvinas on protein degradation

Pfizer has signed on to fund the launch of a hunt for a slate of small molecules that can degrade proteins, a key therapeutic pathway that’s been playing a role in prostate cancer and other areas.
- Source: Endpts
- 489
- January 10, 2018
C4 Therapeutics Market Views Pfizer protein degradation
Increasing Rates of Surgery for Patients With Non-Malignant Colorectal Polyps in the United States

Despite the availability of endoscopic therapy, many patients in the United States undergo surgical resection for non-malignant colorectal polyps. We aimed to quantify and examine trends in the use of surgery for non-malignant colorectal polyps in a nationally representative sample.
- Source: gastrojournal.org
- 368
- January 10, 2018
endoscopic therapy non-malignant colorectal polyps Researches
Busy Takeda Takes Out Tigenix in $630M Deal

Shares of Belgium-based TiGenix NV shot up more than 72 percent in pre-market trading after Japan’s Takeda Pharmaceuticals opted to acquire the company with which it has a developmental partnership for $630 million.
- Source: Biospace
- 513
- January 9, 2018
Market Views pharmaceutical company stem cells
Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS

Sangamo Therapeutics, Inc. and Pfizer Inc. announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
- Source: Prnewswire
- 448
- January 9, 2018
ALS FTLD Market Views neurodegenerative disease
Cancer deaths decline again in US

The cancer death rate in 2015 was 14 percent higher in blacks than in whites, down from a peak of 33 percent in 1993.
- Source: msn
- 546
- January 9, 2018
cancer Death rates smoking
California researchers highlight the benefits of total body scanner

The new total-body PET/CT scanner could revolutionize the understanding and treatment of disease through analysis of better imaging data from the whole body.
- Source: biospectrumasia
- 560
- January 9, 2018
PET PET sensitivity total-body PET/CT scanner
Illumina and KingMed to develop oncology diagnostics in China

US-based gene sequencing firm Illumina has signed an agreement with Guangzhou KingMed Diagnostics Group to co-develop new oncology and hereditary disease testing applications in China.
- Source: Verdict Medical Devices
- 641
- January 9, 2018
cancer CFDA Company Insight digital health
J&J signs 15 deals for new healthcare solutions

Johnson & Johnson (J&J) has signed 15 new partnerships to explore, develop and advance new medical devices, therapeutics and consumer health solutions.
- Source: Verdict Medical Devices
- 706
- January 9, 2018
AI cancer Company Insight Johnson & Johnson

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.